Paper Information

Title: 

"THE EVALUATION OF KIDNEY TRANSPLANTATION OUTCOMES IN HBSAG POSITIVE OR ANTI HCV AB POSITIVE PATIENTS"

Type: PAPER
Author(s): KAMALI KOOSHA*,ZARGAR MOHAMMAD ALI,KHOSRAVANI PARI,HAFEZI REZA
 
 *
 
Name of Seminar: CONGREH ANJOMAN UROLOGY IRAN
Type of Seminar:  CONGRESS
Sponsor:  ANJOMAN OROLOGY
Date:  2005Volume 8
 
 
Abstract: 

PROPOSE: TO EVALUATE THE RESULTS AND COMPLICATIONS OF RENAL TRANSPLANTATION IN HBSAG POSITIVE OR ANTI HCV AB POSITIVE PATIENTS AND COMPARE IT WITH OTHER PATIENTS.
METHODS & MATERIALS: 1615 KIDNEY TRANSPLANTATION FROM LIVING DONOR WAS UNDERTAKEN IN HASHEMI NEJAD HOSPITAL. WE EVALUATE THE RESULTS AND COMPLICATIONS OF RENAL TRANSPLANTATION IN HBSAG POSITIVE OR ANTI HCV AB POSITIVE PATIENTS RETROSPECTIVELY.
RESULTS: A TOTAL OF 41 PATIENTS HAVE HBSAG POSITIVE AND 8 PATIENTS INCLUDE 3 PATIENTS WITH RNA-PCR-HCV POSITIVE HAVE ANTI HCV AB POSITIVE. IN HBSAG POSITIVE PATIENTS, ACCELERATED REJECTION WHICH DIDN’T RESPONSE TO ANT REJECTION THERAPY WERE OCCURRED IN 3 CASES (73%), ACUTE REJECTION IN 13 CASES (31.7%), CHRONIC REJECTION IN 9 CASES (21.9%), ATN IN 2 CASES (4.8%), ZONA IN 2 CASES (4.8%), PNEUMONIA IN ONE CASE (2.4%), UTI IN 4 CASE (9.7%), CONVULSION IN ONE CASE (2.4%), CUTANEOUS LEISHMANIASIS IN ONE CASE (2.4%), SEPTIC ARTHRITIS IN ONE CASE (2.4%), ADVANCED STOMACH CANCER IN ONE CASE (2.4%), MALIGNANT LYMPHOMA OF LIVER IN ONE CASE (2.4%), MYELOFIBROSIS IN ONE CASE (2.4%), UVJ STENOSIS IN ONE CASE (2.4%), UVJ URINARY LEAKAGE IN 2 CASES (4.8%), MORTALITY RATE IN 4 CASES (9.7%) WERE OCCURRED. THE ONE, FIVE AND TEN YEARS GRAFT SURVIVAL RATES WERE 85.3%, 68.2%, 58.5% AND THE ONE, FIVE AND TEN YEARS PATIENT SURVIVAL RATES WERE 97.5%, 92.6%, 92.6% RESPECTIVELY. IN ANTI HCV AB POSITIVE PATIENTS, ACUTE REJECTION WERE OCCURRED IN 5 CASES (62.5%), CHRONIC REJECTION IN 5 CASES (62.5%), ATN IN ONE CASE (12.5%), BACTERIAL PERITONITIS IN ONE CASE (12.5%), HEPATITIS IN ONE CASE (12.5%), UVJ STENOSIS IN 2 CASES (25%), UVJ URINARY LEAKAGE IN ONE CASE (12.5%) WERE OCCURRED. THE ONE AND FIVE YEARS GRAFT SURVIVAL RATES WERE 87.5%, 62.5% AND THE ONE AND FIVE YEARS PATIENTS SURVIVAL RATES WERE 100% AND 100% RESPECTIVELY. IN HBSAG NEGATIVE AND ANTI HCV AB NEGATIVE PATIENTS, THE ONE, FIVE AND TEN YEARS GRAFT SURVIVAL RATES WERE 87.2%, 66.2%, 49.8% AND THE ONE, FIVE AND TEN YEARS PATIENT SURVIVAL RATES WERE 92.8%, 83.7%, 73.3% RESPECTIVELY.
DISCUSSION & CONCLUSION: THE ONE AND FIVE YEARS GRAFT AND PATIENT SURVIVAL RATES IN HBSAG POSITIVE OR ANTI HCV AB POSITIVE PATIENTS WERE APPROXIMATELY SIMILAR TO HBSAG NEGATIVE AND ANTI HCV AB NEGATIVE PATIENTS. ALSO THE COMPLICATIONS OF RENAL TRANSPLANTATION WERE COMPARABLE IN TWO GROUPS. SO WE SUGGEST THAT HBSAG POSITIVE OR ANTI HCV AB POSITIVE RECIPIENTS COULD UNDERGO RENAL TRANSPLANTATION WITH COMPARABLE RESULTS TO OTHER PATIENT.

 
Keyword(s): KIDNEY TRANSPLANTATION, HBSAG, ANTI HCV AB
 
Yearly Visit 4   tarjomyar
 
Latest on Blog
Enter SID Blog